ClinicalTrials.gg
CompletedNCT00760084Updated Aug 8, 2011Results posted

Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

A Phase 2 interventional study of Decitabine in Acute Myelogenous Leukemia and Myelodysplastic Syndrome, sponsored by Eisai Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-08-08.

Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 121 studies testing decitabine in Leukemia, Myeloid, Acute — 20 open to participants now, 33 under way, 2 of them phase 3. Decitabine · Leukemia, Myeloid, Acute.

Enrollment
103rd of 120
10 · median 32
Started
2005
with 3 others
Phase 2
53 of 121
10 open now
Registered
13th of 121
by date
Lead sponsor
4 of 121
Eisai Inc.

Among the 121 studies testing decitabine in Leukemia, Myeloid, Acute, this one is the 103rd largest by enrollment of the 120 interventional ones that give a count, is one of 4 that started in 2005, is one of 53 in phase 2, and was the 13th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

20 of the 121 studies testing decitabine in Leukemia, Myeloid, Acute are open now, in 5 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About decitabine

Decitabine: first FDA approval 2006 (DACOGEN), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 121 studies testing decitabine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The purpose of this study is to provide decitabine to patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) who have completed participation per protocol in the DACO-018 study.

Read the detailed description

The objectives of this trial are:

  • To generate additional information about the overall safety profile,
  • To generate safety information of hepatically or renally impaired patients, as appropriate, and
  • To generate safety information when patients are also taking concomitant medications and/or therapies without trial restrictions when decitabine is administered at a dose of 20 mg/m² over a 1-hour intravenous infusion for 5 consecutive days every 4 weeks in patients with MDS or AML (≥ 30% blasts).

The purpose of this open-label, expanded-access trial is to provide decitabine to patients with AML or MDS who have completed participation per protocol in the DACO-018 study and for whom continuation of treatment with decitabine is indicated, per the opinion of the investigator. In order to continue treatment with decitabine, at a minimum, there must be no disease progression while the patient was participating in the DACO-018 trial and during the period after the patient discontinued from the DACO-018 study and before entering this trial. Patients must enroll in this trial within 8 weeks of discontinuing from the DACO-018 study and not have received any other chemotherapy for their disease during this interim period.

Decitabine will be administered at a dose of 20 mg/m² over a 1-hour intravenous infusion for 5 consecutive days every 4 weeks.

03

Conditions studied

  • Acute Myelogenous Leukemia
  • Myelodysplastic Syndrome

Keywords

  • Acute Myelogenous Leukemia
  • Myelodysplastic Syndrome
  • Dacogen
  • Decitabine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must sign an Institutional Review Board (IRB) -approved form, indicating his/her awareness of the nature of decitabine and its potential hazards prior to initiation of any study-specific procedures or treatment.
  2. Must have had one of the following:

    MDS (de novo or secondary) fitting any of the recognized French-American-British classifications

    OR

    chronic myelomonocytic leukemia (with WBC \<12,000/μL)

    AND

    an International Prognostic Scoring System score of ≥1.5 as determined by complete blood count, bone marrow assessment and bone marrow cytogenetics within 30 days of study entry OR AML (≥ 30 % bone marrow blasts), except M3 or acute promyelocytic leukemia.

  3. Must be age 18 years or older.
  4. Must have completed participation per protocol in the MGI PHARMA DACO-018 decitabine trial.
  5. Must enroll in this trial no more than 8 weeks after discontinuation from the MGI PHARMA DACO-018 trial.
  6. Must have recovered from all toxic effects of all prior therapy.

Exclusion criteria

Exclusion Criteria:

  1. Must not have any other active , other than basal or squamous cell skin carcinoma.
  2. Must not have received in the period after discontinuation from DACO-018 and enrollment into this trial any other chemotherapy agent, including agents, for their disease.
  3. Must not have evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the trial, at the discretion of the principal investigator.
  4. Must not be pregnant or lactating.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    A

    Decitabine will be administered at a dose of 20 mg/m² over a 1-hour intravenous infusion for 5 consecutive days every 4 weeks.

    Drug: Decitabine

Interventions

  • Decitabine is administered at a dose of 20 mg/m² over a 1-hour intravenous infusion for 5 consecutive days every 4 weeks in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML; ≥ 30% blasts).

    Also known as: Dacogen

06

What researchers measure

Primary outcomes

  1. The Number of Subjects With Adverse Events

    Generate safety information when patients were also taking concomitant medications and/or therapies without trial restrictions when decitabine was administered at a dose of 20 milligrams per meter squared (mg/m\^2) over a 1-hour intravenous (IV) infusion for 5 consecutive days every 4 weeks in patients with MDS (\< 30% blasts) or AML (\> 30% blasts).

    Time frame: 3 months

07

Results

Posted Aug 2, 2011

Participant flow

Participant flow — Overall Study
MilestoneDecitabine
Started10
Completed0
Not completed10
Withdrew: Physician decision5
Withdrew: Withdrawal by subject2
Withdrew: Progressive disease3

Outcome measures

PrimaryThe Number of Subjects With Adverse Events

Generate safety information when patients were also taking concomitant medications and/or therapies without trial restrictions when decitabine was administered at a dose of 20 milligrams per meter squared (mg/m\^2) over a 1-hour intravenous (IV) infusion for 5 consecutive days every 4 weeks in patients with MDS (\< 30% blasts) or AML (\> 30% blasts).

Time frame:
3 months
Reported as:
Number · participants
The Number of Subjects With Adverse Events
participantsDecitabine
The Number of Subjects With Adverse Events10

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Decitabine—6/10 (60%)10/10 (100%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventDecitabine
Febrile NeutropeniaBlood and lymphatic system disorders1/10
NeutropeniaBlood and lymphatic system disorders1/10
Cardiac Failure CongestiveCardiac disorders1/10
Cellulitis GangrenousInfections and infestations1/10
Clostridium Difficile ColitisInfections and infestations1/10
Pneumonia Primary AtypicalInfections and infestations1/10
Pseudomonal BacteremiaInfections and infestations1/10
Lung AdenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/10
Hemorrhage IntracranialNervous system disorders1/10
DyspneaRespiratory, thoracic and mediastinal disorders1/10
Most frequent other events
Showing 10 of 67
Most frequent other events
EventDecitabine
FatigueGeneral disorders8/10
NauseaGastrointestinal disorders4/10
CoughRespiratory, thoracic and mediastinal disorders4/10
ConstipationGastrointestinal disorders3/10
DiarrhoeaGastrointestinal disorders3/10
PyrexiaGeneral disorders3/10
Back PainMusculoskeletal and connective tissue disorders3/10
Musculoskeletal PainMusculoskeletal and connective tissue disorders3/10
DyspnoeaRespiratory, thoracic and mediastinal disorders3/10
EpistaxisRespiratory, thoracic and mediastinal disorders3/10

Baseline characteristics

Age Continuous
Age Continuous(years)Decitabine
Mean68.5 ± 11.15
Sex: Female, Male
Sex: Female, Male(Participants)Decitabine
Female2
Male8
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Decitabine
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White8
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)Decitabine
United States10
08

Study locations

1 site
  • Washington University School of Medicine
    St. Louis, Missouri 63110, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2005, a primary completion of Sep 2005 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2011, 5 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2008
First posted
Sep 25, 2008
Start
Jul 2005
Primary completionActual
Sep 2005
CompletionActual
Feb 2008
Results first posted
Aug 2, 2011
Last update
Aug 8, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00760084
Lead sponsor
Eisai Inc.
First posted
Sep 25, 2008
Start date
Jul 2005
Primary completion
Sep 2005
Completion
Feb 2008
Results posted
Aug 2, 2011
Last update
Aug 8, 2011

Study contacts

Akhil Baranwal, MD
study director · Eisai Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Decitabine

Start the discussion